Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
Your view on IOVA
Overview
What the company does, where it operates, and who runs it.
About Iovance Biotherapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frederick G. Vogt
- Headquarters
- 825 Industrial Road, San Carlos, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frederick G. Vogt
- Headquarters
- 825 Industrial Road, San Carlos, CA, US
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.
It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG.
The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Iovance Biotherapeutics, Inc. from FRC's valuation model, read against the market price. IOVA last traded at $7.76; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Iovance Biotherapeutics, Inc.. Starting points for Iovance Biotherapeutics, Inc.: EPS -$0.48, beta 0.76 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Iovance Biotherapeutics, Inc.. Iovance Biotherapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Iovance Biotherapeutics, Inc.. Trailing twelve-month EPS for Iovance Biotherapeutics, Inc. stands at -$0.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$13.56
average of 9 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy7
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.04 | -$0.04 | -$0.38 | -$0.09 |
| Low estimate | -$0.08 | -$0.04 | -$0.51 | -$0.21 |
| High estimate | -$0.03 | -$0.04 | -$0.28 | -$0.03 |
| No. of analysts | 5 | 4 | 6 | 6 |
| Year-ago EPS | -$0.18 | -$0.19 | -$1.09 | — |
| Growth | +75.6% | +78.0% | +64.8% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $128.58M | $133.90M | $418.98M | $593.84M |
| Low estimate | $128.14M | $130.41M | $387.55M | $571.51M |
| High estimate | $129.03M | $138.64M | $461.58M | $620.52M |
| No. of analysts | 5 | 3 | 5 | 7 |
| Year-ago revenue | $86.77M | $71.43M | $263.50M | — |
| Growth | +48.2% | +87.5% | +59.0% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Pulse 2.0, Benzinga; as of Nov 15, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Iovance Biotherapeutics, Inc.. Iovance Biotherapeutics, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALXOALX Oncology Holdings Inc.Biotechnology$144M
- BNTXBioNTech SEBiotechnology$21.2B
- FATEFate Therapeutics, Inc.Biotechnology$149M
- GMABGenmab A/SBiotechnology$31.7B
- IBRXImmunityBio, Inc.Biotechnology$6.4B
- IMCRImmunocore Holdings plcBiotechnology$1.5B
- IMNMImmunome, Inc.Biotechnology$2.2B
- LEGNLegend Biotech CorporationBiotechnology$3.2B
More Biotechnology companies
- MRKRMarker Therapeutics, Inc.NASDAQ$15M
- MRNAModerna, Inc.NASDAQ$90.4B
- MRPIMera Pharmaceuticals, Inc.OTC$55,730
- MRVIMaravai LifeSciences Holdings, Inc.NASDAQ$2.1B
- MRVL.VMarvel Biosciences Corp.TSXV$10M
- MRZMMarizyme, Inc.OTC$39,538
- MSB.AXMesoblast LimitedASX
- MSCL.TOSatellos Bioscience Inc.TSX$202M
- MSLESatellos Bioscience Inc.NASDAQ$9M
- MSRMMushrooms IncOTC$233,727
- MTNBMatinas BioPharma Holdings, Inc.AMEX$384,371
- MTVAMetaVia Inc.NASDAQ$9M
ETFs holding Iovance Biotherapeutics, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.01%
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.87%
- IWMiShares Russell 2000 ETF$76.6B in assets0.10%
- VBVanguard Small-Cap ETF$76.9B in assets0.04%
- IDNAiShares Genomics Immunology and Healthcare ETF$352M in assets2.67%
- PTHInvesco Dorsey Wright Healthcare Momentum ETF$293M in assets2.67%
- BBPVirtus LifeSci Biotech Products ETF$133M in assets2.46%
- CANCTema Oncology ETF$215M in assets1.72%
Largest holders first, then the funds most concentrated in IOVA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Iovance Biotherapeutics, Inc., and how their positions are changing. At a $3.59B market value, institutional positions materially move Iovance Biotherapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Iovance Biotherapeutics, Inc. executives and directors. Shares of Iovance Biotherapeutics, Inc. have traded between $1.64 and $9.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Iovance Biotherapeutics, Inc.. Coverage tracks Iovance Biotherapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Iovance Biotherapeutics, Inc.